Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : LENZ Therapeutics
Deal Size : $125.0 million
Deal Type : Licensing Agreement
LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia
Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 09, 2025
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : LENZ Therapeutics
Deal Size : $125.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Klinge Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lotus Becomes Strategic Partner for the Commercialization of Biosimilar Ahzantive
Details : Through the collaboration, Lotus will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.
Product Name : Ahzantive
Product Type : Protein
Upfront Cash : Undisclosed
February 05, 2025
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Klinge Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Corium
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...
Product Name : Adlarity
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2023
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Corium
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2010
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
